Diagnostics Digest

In this season opener, we sit down with Krista Ewing, Senior Global Product Manager at Porex Corporation. As a renowned global leader in advanced porous solutions across various industries, including medical devices and writing instruments, it provides high-value solutions for product design challenges related to absorption, diffusion, filtration, and more.Nathan chats with Krista about the journey behind the development of TruFlow, the infamous lateral flow product that emerged in response to the challenges faced during the COVID-19 pandemic. The conversation highlights the critical issues of inconsistency in glass fibre materials used for these tests, exacerbated by the soaring demand for COVID-19 diagnostics. Truflow was conceived as a solution to these challenges, aiming to provide more dependable and uniform materials for lateral flow tests, ultimately enhancing the accuracy and reliability of these crucial diagnostics.Press play to learn about the journey and significance of TruFlow in revolutionising lateral flow testing and the impressive teamwork driving its success. Hosted on Acast. See acast.com/privacy for more information.

This is the final episode of our 3-part series with the exciting POC diagnostics start-up, ProtonDx.ProtonDx is founded on a decade of research and development at Imperial College London. Its vision is to develop ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need. In 2022, the business received a CE mark for its cutting-edge Dragonfly product. Now the ProtonDx team are looking to commercialise this essential testing kit.In this episode, CM Life Science Business Manager, Nathan Sharpe, speaks to the Co-Founder and Chief Technology Officer of ProtonDx, Dr. Nicolas Moser. Nicolas earned an MSc at Imperial College London with distinction and received the Hertha Ayrton Centenary Prize (best MSc project) and the MSc Analogue and Digital Integrated Circuit Design Outstanding Achievement Prize (highest ranking MSc student).In this episode, we cover the future of diagnostics from the perspective of an award-winning scientist and industry innovator. If you would like to learn more about the new possibilities with lab-on-chip, then be sure to give it a listen. Hosted on Acast. See acast.com/privacy for more information.

In this next episode of our 3-part series with the exciting POC diagnostics start-up, Nathan sits down with Bob Enk, Chairman & President, and Dr. Jesus Rodriguez Manzano, Chief Scientific Officer for an exclusive chat about the future of diagnostics with ProtonDx.Dr. Rodriguez Manzano has a strong interdisciplinary background in microbiology, molecular biology and bioengineering, and his research interest includes single-molecule technologies, machine learning applied to healthcare, and clinical diagnostics, with a particular interest in low- and middle-income countries. He is the author of over 90 scientific publications and 14 international patent applications and helped co-found ProtonDx just over 3 years' ago.Bob Enk is Chairman and President at ProtonDx. An experienced investing pioneer and CEO with an alternative mindset and demonstrated history of innovation and growth across financial services and healthcare. After joining the business nearly 2 years ago to take it to the next level in its stratospheric growth, he offers insight into his industry experience interacting with key players and clients, working with strategic partners and major investors, and loads more.From the stimulus for this impressive brand to the reality of using point-of-care to tackle infectious disease in 2023 and beyond. Listen to learn more about new possibilities with lab-on-chip, the vision for developing ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need, and the plan to commercialise this essential testing kit. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we begin our 3-part series with the exciting POC diagnostics start-up, ProtonDx.ProtonDx is founded on a decade of research and development at Imperial College London. Its vision is to develop ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need. In 2022, the business received a CE mark for its cutting-edge Dragonfly product. Now the ProtonDx team are looking to commercialise this essential testing kit.Our conversations started with the co-founder and CEO, Professor Pantelis Georgiou. Pantelis holds the position of Professor of Biomedical Electronics at Imperial College London. He heads the Bio‑inspired Metabolic and Infection Technology Laboratory in the Centre for Bio‑Inspired Technology; a multi‑disciplinary group that invents, develops and demonstrates advanced micro‑devices to meet global challenges in biomedical science and healthcare. His research includes applications of lab‑on‑chip technology for genomics and diagnostics targeted towards infectious disease and cancer.In this episode, CM Life Science Business Manager, Nathan Sharpe, asks Pantelis about the mission that ProtonDx is on: getting molecular testing to the point-of-need. If you are interested in learning more about this ambitious start-up, then be sure to have a listen.  Hosted on Acast. See acast.com/privacy for more information.

In this episode of Diagnostics Digest, CM Life Science Business Manager Nathan Sharpe speaks with Kevin Fallon, CEO & Co-Founder of FlexMedical Solutions.Since 2016 FlexMedical has been on an exciting journey, jumping from strength to strength. From significant headcount growth to major investment in both equipment and facilities, the business has become one of the most trusted IVD manufacturers in the world in its short lifespan. Now, they're ready to make the next big move.Our team went to visit FlexMedical at their Scottish HQ, where Nathan caught up with Kevin to discuss the company's exciting plans as one of the world's go-to IVD manufacturers. Find out behind the scenes from the journey to the top, the impact of significant growth, and loads more in this fascinating chat.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please get in touch at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

In this episode, CM Life Science Business Manager, Nathan Rigby, speaks with Erez Naaman, Co-Founder & CTO at Scopio Labs.Prior to Scopio Labs, Erez was VP of Engineering & Business Development at OrCam, a leading Israeli high-tech start-up. He brings much of his insight from this experience to this discussion, as well as insight into the development of his current business, trends in AI and how he believes this affects the future of healthcare.Scopio Labs uses full-field digital cell morphology to automate the analysis of tens of thousands of cells at a time – far more than any human can quantify, bringing dramatically earlier detection and diagnosis of cancers, infections, and other diseases. This technology expedites patients’ access to better care and life-saving treatments, with a key focus on digitizing microscopy and bringing it to the modern age. By providing access to rapid diagnostic tools for the first time. This system includes uniquely built-in computational power to enable AI at the user's fingertips - saving time, enabling collaboration, improving data safety and reducing the need for expensive hardware.If you're interested in hearing more about Erez and his company, or are fascinated by what AI brings to the future of the space, then be sure to have a listen.To find out more about Nathan and his work in the diagnostic space, get in touch at nathan.rigby@lifesci-cm.com or connect on LinkedIn to chat. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Nathan speaks with Richard Acton, former CSO at Cignpost Diagnostics, about transitioning a company from a COVID testing business to a health and wellness business.Cignpost Diagnostics is a leading health and diagnostics company, operating globally to empower and guide people towards living a healthier life. By combining scientific expertise with a relentless focus on people, Cignpost has quickly evolved to become a global leader in COVID-19 screening and health diagnostics, establishing safe, managed environments across a range of sectors, including elite sports, defence, film and TV production, and financial services.Richard has an extensive history growing and accelerating businesses in the point-of-care market, working on R&D, lab operations, quality and clinical functions and plenty more. With experience gaining certification in the space and working to lead scientific operations for a COVID testing company throughout the pandemic sees Richard share exciting insight and knowledge from his time at Cignpost.If you are interesting in learning about all things POC from the perspective of a company at the forefront of innovation who is well versed in diversification and overcoming challenges to create success, then be sure to have a listen.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please get in touch at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with David Wells, Chief Executive Officer of the Institute of Biomedical Science (IBMS).With over 21,000 members in 74 countries, IBMS is the leading professional body for scientists, support staff and students in the field of biomedical science. For over 100 years, it has been dedicated to the promotion, development and delivery of excellence in biomedical science within all aspects of healthcare, and to providing the highest standards of service to patients and the public.We discuss the NHS response to rapid testing, the importance of the IBMS and its members as an organisation and what's to come during its biggest conference. Until June 2021 David led the NHS England and NHS Improvement Pathology consolidation programme, seeking to deliver efficient, high quality and innovative pathology services across England.Now appointed Chief Executive of the IBMS, as an expert advising on policy, strategy and technology deployment, he shares fascinating insights from his experiences at the helm of the biggest healthcare challenge the world has ever seen.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please drop me a message at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Eleanor speaks with Delphine Galezowski, Director of Market Development in Europe for Adaptive Biotechnologies.We discuss European market expansion strategies within the diagnostics space, the differences between European market access and other global territories, and insights from her time leading teams at AstraZeneca.Whether you’re in the diagnostics industry, are intrigued by market access strategies, or are wondering how different organisations and regions differ within the market – then be sure to have a listen.In the following episodes my colleagues will be discussing a range of key trends and insights into key topics within the wider diagnostics market, too. So please subscribe to the series to be notified when their episodes become available.If you'd like to get in touch about this episode, would like to be a future podcast guest or want to learn more about CM Life Science's services; then please email me at eleanor.doolin@lifesci-cm.com. Hosted on Acast. See acast.com/privacy for more information.

In the final part of this three-part episode, Dennis and Adam discuss new technologies to watch in the liquid biopsy market, as well as insights into innovation from behind the scenes at Predicine.Dennis touches on how to become a legendary company in your market, and what this means in liquid biopsy terms. A truly eye-opening discussion which anyone would be sure to gain something from.In parts one and two, we discussed the importance of liquid biopsy for the future oncology market as well as strategies for overcoming barriers when entering new markets. A huge thanks to Dennis for coming on to share his knowledge and experience.If you'd like to get in touch about this episode, be a future podcast guest, or learn more about CM Life Science's services, please email Adam at adam.hargeaves@lifesci-cm.com. Hosted on Acast. See acast.com/privacy for more information.

In part two of this three-part discussion, Adam and Dennis discuss the key barriers for entry for companies expanding into new territories and how to overcome these, whether you're a start-up or established company entering the market.Dennis brings insight from his broad and brilliant background in molecular oncology and precision medicine, with experience in all elements from research to pharma and commercial. Discussing the challenges and opportunities he's faced as the CEO of Predicine in Europe.This conversation comes in three parts. In part one, the pair discussed the importance of liquid biopsy for the future oncology market. Part three discusses new liquid biopsy technologies and what's new at Predicine. Be sure to subscribe to be notified when all parts are available.If you'd like to get in touch about this episode, be a future podcast guest, or learn more about CM Life Science's services, please email Adam at adam.hargeaves@lifesci-cm.com. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Diagnostics Digest, Adam speaks to Dennis Merkle, CEO of Europe and Global Head of Biopharma Business for molecular insights company, Predicine.Dennis brings insight from his broad and brilliant background in molecular oncology and precision medicine, with experience in all elements from research to pharma and commercial. Here we jump into a well-rounded discussion on the benefits of liquid biopsy in today's oncology market.This conversation comes in three parts. In part two, we delve into critical barriers within the market and how to overcome these. Part three discusses new liquid biopsy technologies and what's new at Predicine. Be sure to subscribe to be notified when all parts are available.If you'd like to get in touch about this episode, be a future podcast guest, or learn more about CM Life Science's services, please email Adam at adam.hargeaves@lifesci-cm.com. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with Beth Cobb, Chief Operating Officer at NOWDiagnostics | NowDx.NOWDx is on a mission to develop rapid, accurate, affordable, and easy-to-administer over-the-counter and point-of-care diagnostic tests that return results in minutes. This innovative product is accompanied by a vision to create a world with vastly improved access to accurate healthcare information. Through providing access to quick and easy at home testing, patients and caregivers become empowered with the knowledge and understanding to truly change the future of disease management.In this episode, we discuss diversity and gender equality in the start-up and diagnostics space, and what this landscape means for the future of NOWDx and others in the market. Priding themselves on striving to make a difference to people's lives, both colleagues and customers, Beth delves into the challenges and strategies she has experiences when doing just that.Whether you’re in the diagnostics industry or not, this episode promises invaluable insight for those looking to change their company DEI agenda for the better.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please drop me a message at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with Wendy Harman, Vice President of Product and Commercial at Weavr Health.After being selected as one of the Built In Boston 'Best Small Companies To Work For', and announcing its recent Labcorp partnership, we discuss the successes and challenges of retaining a core company culture when scaling a fast-growing start-up. From how to build a company culture that attracts the best talent, to what makes their innovative approaches and technologies different to others in the market, Wendy shares plenty of insight you won't want to miss. Wendy also discusses Weavr’s partnership with Nightingale Health, who recently announced the availability of the Livit service to the UK.Whether you’re in the diagnostics industry or not, this episode has some invaluable info for those looking to change an industry's approach to company culture.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please drop me a message at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn. Hosted on Acast. See acast.com/privacy for more information.